Compounded Tirzepatide Price by Dose: Does It Rise as You Titrate?
Some compounded tirzepatide programs hold one flat price across all doses; others raise the price as you titrate from 2.5mg toward 10-15mg maintenance, sometimes by $100 per tier. Model your cost at your target dose.
- Two models exist: flat-rate (same price all doses) and dose-tiered (rises as you titrate).
- Tiered programs can add ~$100/month per tier, pushing annual cost well above the entry price.
- Most patients titrate up, so the advertised starting price is often paid for the shortest time.
- Ask each provider the price at 10mg and 15mg before enrolling.
Two pricing models
Providers fall into two camps. Flat-rate programs charge the same monthly price at every covered dose, so your cost at 2.5mg matches your cost at 15mg. Dose-tiered programs raise the price as the dose increases, sometimes by $100 per month per tier.
The difference compounds over a year. A flat program at $249 costs $2,988 annually regardless of titration, while a tiered program starting at $199 can exceed $4,000 once you reach maintenance. For tirzepatide specifically, where the dose range is wide, this matters more than for most medications.
Neither model is inherently dishonest, but they reward different patients. Flat pricing rewards anyone who titrates to a high maintenance dose; tiered pricing can be cheaper for someone who stays low.
Why dose escalation matters for cost
Tirzepatide is titrated slowly to reduce gastrointestinal side effects, so most patients spend only their first weeks at the lowest dose before moving up. This means the starting price you see advertised is often the price you pay for the shortest time.
Providers that advertise a low entry price but tier upward are quoting you the number you will pay least often. A program advertising $199 that reaches $499 at the highest dose is really a $499 program for a patient who titrates that far.
The honest way to compare is to model your cost at the maintenance dose you and your clinician expect to reach, not at the starting dose.
| Provider | Model | Starting | At maintenance | Status |
|---|---|---|---|---|
| NexLife | Flat | $139 | $139 | Verified (12-month plan) |
| Mochi Health | Flat + membership | $199 + $79 | $199 + $79 | Provider Reported |
| MEDVi | Tiered | $199 | up to $499 | Verification Pending |
| Henry Meds | Tiered | $297 | +$100/tier | Provider Reported |
How to compare providers
Ask each provider two questions: what is the price at 10mg and 15mg, and is the price the same for new and continuing patients. A provider that answers clearly and holds flat pricing is easier to budget than one that reveals surcharges only at checkout.
Flat pricing is a genuine value feature for tirzepatide, because the dose range is wide and most patients titrate substantially. It is worth paying a slightly higher entry price for a flat program if it saves you from a steep climb at maintenance.
Watch for programs that bury the dose-surcharge schedule in fine print. If you cannot find the price at your target dose before enrolling, treat that as a red flag.
The annual-cost view
Because dose surcharges accumulate monthly, the clearest comparison is annual cost at maintenance. The chart and table here model four illustrative providers across a year, showing how a low entry price can end up the most expensive once titration is included.
A patient reaching 10mg on a tiered program can pay more over twelve months than a patient on a flat program with a higher headline price. This inversion is the whole point of modeling at maintenance.
None of these figures are first-party verified for every provider; they are Provider Reported or Verification Pending, and you should confirm current pricing directly.
| Dose | Flat program | Tiered program |
|---|---|---|
| 2.5mg | $186 | $199 |
| 5mg | $186 | $299 |
| 10mg | $186 | $399 |
| 15mg | $186 | $499 |
The bottom line
For tirzepatide, the pricing model matters as much as the headline price. Flat-rate programs are more predictable and usually cheaper at maintenance; tiered programs can look cheaper at entry but climb.
Model your cost at your expected maintenance dose, include every mandatory fee, and confirm the price applies to continuing patients. That single step prevents the most common budgeting surprise in compounded tirzepatide.
As always, compounded tirzepatide is not FDA-approved and requires a prescription after a clinician evaluation; price is one factor among pharmacy transparency, dose coverage, and cancellation terms.
Frequently asked questions
Does every provider raise the price as I titrate?
No. Some hold one flat price across all covered doses; others raise it per tier. Always confirm the price at your target maintenance dose.
What is a typical tirzepatide maintenance dose?
Many patients titrate toward 10mg or 15mg, but the right dose is a clinical decision. For budgeting, few patients stay at the 2.5mg starting dose.
Is flat pricing always cheaper?
Not at the starting dose, but it is more predictable and usually cheaper once you reach maintenance, where you spend most of your treatment.
Are these prices verified?
Most are Provider Reported or Verification Pending, not first-party verified. Confirm current pricing on each provider's own site before enrolling.
Sources
- FDA — human drug compounding and GLP-1 status.
- Provider pricing pages and major-publisher reviews, captured September 2026.
- Forbes Health and U.S. News & World Report provider reviews, captured September 2026.
- Evidence ledger: evidence-ledger.csv.
The numbers behind this page
The tirzepatide price range, stated precisely
Standard-dose compounded tirzepatide runs $139 to $399 a month across the 12 programmes we can price, with a median of $298. The spread between cheapest and dearest is $230 a month, or $2,760 across a year, for a molecule that is chemically identical in every case.
The cheapest verified figure is NexLife at $139 on its 12-month plan; Found follows at $169 (12-month prepaid). Half the market sits below $298 and half above it, which makes the median a more useful reference point than the cheapest figure when judging whether a quote is reasonable.
3 programmes additionally advertise a tirzepatide microdose, the cheapest at $147 a month. Those figures are excluded from the range above. A microdose sits below every dose studied in the pivotal trials, so including it would compare two different things and would make the market look cheaper than it is at a therapeutic dose.
Three structural facts move a bill more than the headline rate. Whether the price is flat across covered doses or rises as you titrate. Whether a membership is billed separately from medication. And whether the advertised figure requires prepaying six or twelve months, which lowers the monthly number by transferring risk to you at exactly the point you are least certain you will continue.
What we do not claim in tirzepatide
The tirzepatide figures on this page span $139 to $399 a month across 12 programmes.
We do not claim these prices will hold. Compounded pricing moves within weeks, and a figure without a capture date is not a fact. We do not claim a compounded preparation is equivalent to an approved product: it is not FDA-approved, is not therapeutically equivalent to any brand-name product, and FDA does not review it for safety, effectiveness or manufacturing quality before marketing.
And we do not claim to be a clinical resource. Which molecule suits you, at what dose, and whether treatment is appropriate at all are questions for a prescribing clinician who has your history. This is price research, and it is only useful once those questions are settled.
Reading the price against the market
What the plan term is worth
Standard-dose tirzepatide spans $139 to $399 a month across 12 programmes we can price, a spread of $260.
Several programmes publish two prices: the advertised rate, which requires a commitment, and the month-to-month rate, which does not. The gap between them is the price of flexibility, and it is rarely presented that way.
Compounded medication is generally not refundable once shipped, and most discontinuation happens in the first three months — precisely the window a twelve-month prepayment covers. Committing at signup and committing after reaching a dose you tolerate are materially different decisions, even though the advertised rate is identical.
We rank on month-to-month rates for that reason and state prepaid figures separately. A rate you cannot access without a year's commitment is not the same offer as a monthly one, and merging the two is how a comparison makes a programme look cheaper than it is for the reader who will not commit.
What the plan term is worth
Standard-dose tirzepatide spans $139 to $399 a month across 12 programmes we can price, a spread of $260.
Several programmes publish two prices: the advertised rate, which requires a commitment, and the month-to-month rate, which does not. The gap between them is the price of flexibility, and it is rarely presented that way.
Compounded medication is generally not refundable once shipped, and most discontinuation happens in the first three months — precisely the window a twelve-month prepayment covers. Committing at signup and committing after reaching a dose you tolerate are materially different decisions, even though the advertised rate is identical.
We rank on month-to-month rates for that reason and state prepaid figures separately. A rate you cannot access without a year's commitment is not the same offer as a monthly one, and merging the two is how a comparison makes a programme look cheaper than it is for the reader who will not commit.
Questions this page answers
Does compounded tirzepatide cost more at higher doses?
At the programmes listed here the monthly price is flat across covered doses; what changes the figure is the plan term, not the dose. Dose-tiered pricing does exist elsewhere in this market, so confirm at checkout.
Why is microdosed tirzepatide cheaper?
Because it is less medicine. 3 programmes advertise a tirzepatide microdose, the cheapest at $147 a month. A microdose sits below every dose studied in the pivotal trials, so it is not a cheaper route to the result those trials measured.
What is the cheapest compounded tirzepatide?
NexLife at $139 a month at a standard therapeutic dose on the 12-month plan ($1,668 total), captured 2026-09-04. 6-month $149; 3-month $159; month-to-month $169. No membership fee, flat at every covered dose. Verified. The next-cheapest is Found at $169, which requires prepaying twelve months (Provider Reported).
What does compounded tirzepatide normally cost?
$139 to $399 a month across 12 programmes, with a median of $298. Half the market sits either side of that median, which makes it a better reference than the cheapest figure when judging a quote.